MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
GLTO - Galecto Inc
$2.98
-0.09(-2.93%)6:00:00 PM 11/26/2021
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap76M
PE Ratio
PEG Ratio-0.1
P/B
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %1%
Held by Institutions %60%
1 Day Vol Adjusted Return-0.9
1 Month Vol Adjusted Return-3.2
3 Month Vol Adjusted Return-14.0
6 Month Vol Adjusted Return-19.5
20 Days SMA Price ZScore-1.3
50 Days SMA Price ZScore-1.8
12 -26 Days PPO-4.4
1 Month Average Short Volume Ratio29.9
1 Day Volume Change ZScore-1.3
1 Month Daily Vol3.2
Related Topics
leak data

Related Topics

Stock news

    11/4/2021GLTO
    Galecto Reports Third Quarter Operating and Financial Results

    Announces clinical collaboration with Roche for first line NSCLC Remains on track with clinical data milestone timing BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended September 30, 2021. “The third quarter continued to show strong execution by the Galecto team, as we initiated enrollment in

    11/2/2021GLTO
    Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting

    Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung cancer (NSCLC). Under the agreement terms, Galecto will fund and conduct a Phase 2a trial to investigate the combination of GB1211 and Roche's atezolizumab (Tecentriq) for the treatment of first-line NSCLC. The Company plans to initiate the Phase 2a combination study during 1H of 2022 and anticipa

    11/2/2021GLTO
    Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer

    Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer Additional information relating to Galecto’s oncology programs will be provided at upcoming R&D Day on November 8, 2021 BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has entered into

    10/28/2021GLTO
    Galecto Hosting a Key Opinion Leader Webinar on GB1211: A Potential Treatment For Non-Small Cell Lung Cancer

    Monday, November 8th @ 10:30am ETBOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a key opinion leader (KOL) webinar on BG1211 and its potential as a treatment for non-small cell lung cancer, on Monday, November 8, 2021 at 10:30am Eastern Time. The event will feature presentations from KOLs Alexander M.M. Eggermont, MD, PhD, Princ

    10/26/2021GLTO
    Galecto to Present at Upcoming Investor Conferences

    BOSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Galecto’s management team will be presenting virtually at the Credit Suisse Healthcare Conference and in-person at the Jefferies London Healthcare Conference. Galecto’s management team will be available for 1x1 meetings at both of these conferences. Details for the presentations are below: Credi

    10/2/2021GLTO
    Penny Stocks to Buy Using Technical Analysis for October 2021

    Technical analysis can help investors find profitable trades without having to pore over conference call transcripts and newspapers.

    09/15/2021GLTO
    Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference

    BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Company’s Chief Executive Officer, will be presenting on Tuesday, September 28, 2021 at 8:40 AM ET and will be available for 1x1 meetings on the same date. A live audio webcast will be available on the "Webcasts & Presentations" section of Galecto’s Investor website at https:

    09/13/2021GLTO
    Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

    Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indicationsBOSTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of novel treatments for fibrosis and cancer, today announced that the first patient has been treated with the galectin-3 inhibitor GB1211 in the Phase 1b/2a GULLIVER-2 trial. This trial marks the initiation of Galecto’s clinical program for GB1211 in l

    08/18/2021GLTO
    Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial

    Galecto Inc (NASDAQ: GLTO) has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelofibrosis, a form of chronic leukemia, is a rare type of blood cancer in which the normal bone marrow is destroyed by fibrous scar tissue that does not produce blood cells. The open-label MYLOX-1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GB2064 in 16 patients over 9 mont